Results 271 to 280 of about 47,434 (363)

Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma. [PDF]

Mol Biomed
Fang CY, Wen J, Wu JD, Li ZC, Huang S, Huang Y, Chen JY, Su HL, Xie XY, Luo KJ, Fu JH, Yang H.   +11 more
europepmc   +1 more source

P2.01-39 Serial Plasma ctDNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M+ NSCLC [PDF]

, 2019
Bin-Chi Liao, Wei‐Ting Hsu, Jih‐Jong Lee, James Chih‐Hsin Yang, Tun‐Jun Tsai, Wei‐Yu Liao, Chao‐Chi Ho, Chia‐Chi Lin, Jin‐Yuan Shih, Chong‐Jen Yu, James Chih‐Hsin Yang   +10 more
openalex   +1 more source

Breast Cancer: Molecular Pathogenesis and Targeted Therapy

MedComm, Volume 6, Issue 10, October 2025.
Dysregulation signaling pathways in various breast cancer subtypes and their targeting using different inhibitors. ABSTRACT Breast cancer (BC) is the most prevalent cancer in women and remains the leading cause of cancer‐related mortality globally.
Md Abdus Samad, Iftikhar Ahmad, Mohammad Rashid Khan, Mohd Suhail, Torki A. Zughaibi, Fahad A. Al‐Abbasi, Khaled A. Alhosaini, Mohd Shahnawaz Khan, Ajoy Kumer, Shams Tabrez   +9 more
wiley   +1 more source

Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis. [PDF]

JCO Precis Oncol
Lu D, Lin N, Li S, Jing Q, Yin JC, Shi L, Zhang Z, Chen Z, Wang Z, Tong Y, Zhai J, Feng S, Cai K.   +12 more
europepmc   +1 more source

P1.14-56 The Dynamic Range of Mutant Allele Fraction Detected in ctDNA from Patients with NSCLC: Clinical Experience Data and Clinical Implications [PDF]

, 2019
Smitha Boorgula, Julie Ann Mayer, Deanna Fisher, Veena Singh   +3 more
openalex   +1 more source

The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances

MedComm, Volume 6, Issue 10, October 2025.
Immunotherapy, serving as a crucial breakthrough of precision medicine in the field of cancer treatment, among which immune checkpoint inhibitors (ICIs) have witnessed the most extensive application. This review systematically investigates the challenges, advancements, and future directions of ICIs in tumor treatment.
Hengyi Chen, Hongling Yang, Lu Guo, Qingxiang Sun   +3 more
wiley   +1 more source

TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

, 2019
Yoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, Hiroko Hasegawa, Ken Kato, Satoru Iwasa, Taito Esaki, Yoshito Komatsu, Toshiki Masuishi, Tomohiro Nishina, Shogo Nomura, Makoto Fukui, Seiko Matsuda, Akihiro Sato, Satoshi Fujii, Justin I. Odegaard, S. Olsen, Takayuki Yoshino   +17 more
openalex   +1 more source

EP1.12-37 Higher Consistency of Mutations Between Tumor DNA and ctDNA in Small-Cell Lung Cancer Compared to Non-Small Cell Lung Cancer [PDF]

, 2019
Hongxia Ma, Chao Li, Jing Ma, H. Wang, Feiran Lou, S. Cao, You‐cai Zhu, Lihong Tong, Qi Zhang, X. Wang, Tao Wang, Wenjun Chang   +11 more
openalex   +1 more source

Circulating Tumor DNA in Pediatric Mature B‐Cell Non‐Hodgkin Lymphoma for Genotyping and Minimal Disease Monitoring

Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.
ABSTRACT Background Early detection of treatment failure in pediatric patients with mature B‐cell non‐Hodgkin lymphoma (NHL) could improve treatment stratification. Analysis of circulating tumor DNA (ctDNA) has been established as a biomarker in adult patients with mature B‐cell NHL (B‐NHL); however, data on ctDNA in pediatric mature B‐NHL are lacking.
Jana Werner, Christine Damm‐Welk, Marius Rohde, Patrick Hundsdörfer, Simon Vieth, Axel Karow, Anke Barnbrock, Wolfram Klapper, Julia Richter, Carla Koslowski, Luisa Kruppa, Malik Alawi, Amelie Alfert, Birgit Burkhardt, Wilhelm Wößmann, Fabian Knörr   +15 more
wiley   +1 more source

ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma. [PDF]

Cell Rep Med
Liu Z, Wang G, Yang Y, Su Y, Zhang H, Liu J, Cui P, Fan X, Yang J, Zhang Z, Gao X, Chao Y, Mostert B, van Lanschot JJB, Wijnhoven BPL, Law S, Li C, Cai S, Li Z.   +18 more
europepmc   +1 more source